Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3847690 | American Journal of Kidney Diseases | 2014 | 13 Pages |
Abstract
Use of end points based on 30% or 40% eGFR declines is an appropriate strategy to reduce sample size in certain situations. However, risk for type 1 error is increased in the presence of acute effects, particularly for 30% eGFR declines. The decision to use these end points should be made after thorough evaluation of their expected performance under the conditions of specific clinical trials.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Tom PhD, Chia-Chen MS, Lesley A. MD, MS, Andrew PhD, Jian PhD, Mark PhD, Josef MD, PhD, Andrew S. MD,